Michael W. Ruff, M.D.

Closed for Enrollment

• ONC018 Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas Rochester, Minn.

  The purpose of this project is to provide expanded access to ONC201 for patients with previously-treated H3 K27M-mutant and/or midline high grade gliomas who cannot access ONC201 through clinical trials.

• ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (ACTION) Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

  The purpose of this study is to evaluate the effectiveness of ONC201 administered following radiotherapy in participants with H3 K27M-mutant diffuse glioma.